[go: up one dir, main page]

MX2017011170A - Peptidos para inhibir la angiogenesis. - Google Patents

Peptidos para inhibir la angiogenesis.

Info

Publication number
MX2017011170A
MX2017011170A MX2017011170A MX2017011170A MX2017011170A MX 2017011170 A MX2017011170 A MX 2017011170A MX 2017011170 A MX2017011170 A MX 2017011170A MX 2017011170 A MX2017011170 A MX 2017011170A MX 2017011170 A MX2017011170 A MX 2017011170A
Authority
MX
Mexico
Prior art keywords
peptides
inhibiting angiogenesis
methods
relates
present
Prior art date
Application number
MX2017011170A
Other languages
English (en)
Inventor
A Komarova Yulia
B Malik Asrar
Rosenblatt Mark
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2017011170A publication Critical patent/MX2017011170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00844—Feedback systems
    • A61F2009/00851—Optical coherence topography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00863—Retina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00865—Sclera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00872—Cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a péptidos para inhibir la angiogénesis. La presente invención también se refiere a métodos para inhibir la angiogénesis y métodos para tratar trastornos asociados con la permeabilidad vascular inducida por VEGF usando los péptidos de la invención.
MX2017011170A 2015-03-02 2016-03-02 Peptidos para inhibir la angiogenesis. MX2017011170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562126968P 2015-03-02 2015-03-02
PCT/US2016/020443 WO2016141053A1 (en) 2015-03-02 2016-03-02 Peptides for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
MX2017011170A true MX2017011170A (es) 2018-04-24

Family

ID=55543089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011170A MX2017011170A (es) 2015-03-02 2016-03-02 Peptidos para inhibir la angiogenesis.

Country Status (18)

Country Link
US (2) US9675660B2 (es)
EP (1) EP3265110B1 (es)
JP (1) JP6896641B2 (es)
KR (1) KR20170122762A (es)
CN (1) CN107427549B (es)
AU (1) AU2016226264B2 (es)
BR (1) BR112017018665A2 (es)
CA (1) CA2977389A1 (es)
DK (1) DK3265110T3 (es)
ES (1) ES2820710T3 (es)
IL (1) IL253966B (es)
MX (1) MX2017011170A (es)
PH (1) PH12017501549B1 (es)
PL (1) PL3265110T3 (es)
RU (1) RU2708375C2 (es)
SG (1) SG11201706799YA (es)
WO (1) WO2016141053A1 (es)
ZA (1) ZA201705934B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112175A1 (en) * 2018-09-11 2020-03-19 Anbition S.R.L. Peptides and medical uses thereof
CN112996528B (zh) * 2018-09-11 2025-01-07 安必圣有限责任公司 肽及其医学用途
CN113755634A (zh) * 2021-10-12 2021-12-07 河南省农业科学院烟草研究所 一种鸢尾丝囊霉菌分子检测的特异引物及其检测方法
CN115737677B (zh) * 2022-07-25 2024-09-06 天津医科大学总医院 一种多肽修饰的金纳米颗粒在制备抑制糖尿病视网膜病变药物中的用途
KR102587729B1 (ko) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
JP2007509984A (ja) * 2003-10-29 2007-04-19 ザ・ジョンズ・ホプキンス・ユニバーシティ 色素上皮由来因子、その新規な生物活性及びその使用方法
US7368430B2 (en) 2003-11-06 2008-05-06 Research Development Foundation Selective inhibitors of nuclear factor-κB activation and uses thereof
JP2008509157A (ja) * 2004-08-06 2008-03-27 ソフェリオン セラピューティクス，インコーポレイテッド 抗血管新生ペプチドおよびその使用方法
WO2009032477A2 (en) * 2007-08-08 2009-03-12 The Board Of Regents Of The University Of Texas System Vegfr-1/nrp-1 targeting peptides
KR20100133881A (ko) * 2008-04-16 2010-12-22 유니버시티 오브 유타 리써치 파운데이션 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
US20100190691A1 (en) 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
EP2439514A1 (en) 2010-10-01 2012-04-11 Aqsens Oy Method, apparatus, and system for examining optically a sample carried in a plurality of wells
AU2012271781C1 (en) * 2011-06-13 2017-09-21 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
CN102286101B (zh) * 2011-08-08 2013-05-08 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用

Also Published As

Publication number Publication date
HK1247573A1 (zh) 2018-09-28
EP3265110A1 (en) 2018-01-10
US10064911B2 (en) 2018-09-04
ES2820710T3 (es) 2021-04-22
IL253966A0 (en) 2017-10-31
KR20170122762A (ko) 2017-11-06
PH12017501549B1 (en) 2021-12-15
RU2708375C2 (ru) 2019-12-06
WO2016141053A1 (en) 2016-09-09
CN107427549B (zh) 2022-01-11
HK1248101A1 (zh) 2018-10-12
IL253966B (en) 2019-12-31
CA2977389A1 (en) 2016-09-09
AU2016226264A1 (en) 2017-08-31
EP3265110B1 (en) 2020-07-15
JP6896641B2 (ja) 2021-06-30
RU2017133101A3 (es) 2019-07-26
DK3265110T3 (da) 2020-10-19
BR112017018665A2 (pt) 2018-04-24
ZA201705934B (en) 2018-12-19
US20160256518A1 (en) 2016-09-08
AU2016226264B2 (en) 2021-04-01
JP2018508528A (ja) 2018-03-29
PL3265110T3 (pl) 2020-12-28
US20170258868A1 (en) 2017-09-14
SG11201706799YA (en) 2017-09-28
PH12017501549A1 (en) 2018-02-05
US9675660B2 (en) 2017-06-13
CN107427549A (zh) 2017-12-01
RU2017133101A (ru) 2019-04-02

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2021002897A (es) Metodos de tratamiento y prevencion de la disfuncion endotelial utilizando metil bardoxolona o sus analogos.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2021014955A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
TN2017000099A1 (en) Triazolopyrazinones as pde1 inhibitors.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12017501549A1 (en) Peptides for inhibiting angiogenesis
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
PH12017501864A1 (en) Compositions and methods for treating autism
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
PH12017501872A1 (en) Methods of treating diseases
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
GB201504587D0 (en) Improvements in methods of treating tobacco.
SI3233110T1 (sl) Ciklični acetilholinesterazni c-terminalni peptid pri zdrvaljenju ali preprečevanju raka ali metastaz
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis